LATE BREAKING ABSTRACT SUBMISSION GUIDELINES

ENDO 2022 will take place at the Georgia World Congress Center in Atlanta, GA from June 11-14, 2022. Please read the following Abstract Submission Guidelines prior to submitting your abstract. If you have any questions not answered within this document you can email abstracts@endocrine.org. Failure to comply with the below guidelines may lead to an abstract being rejected.

Abstract Submission Dates

The ENDO 2022 Late Breaking Abstract Submission site opens on Tuesday, March 29, 2022 and closes on Monday, April 18, 2022 at 1:00 PM EST US.

Abstract Publication

All accepted abstracts will be published on the meeting website and in a supplemental issue of the Open Access Journal of the Endocrine Society (JES), assigned a DOI, and indexed in PubMed and PubMed Central.

Abstract Selection

Authors of accepted abstracts will receive presentation details, and information and technical guidelines on how to prepare for their oral, rapid fire, poster plus, and e-poster on demand presentation. Presenting authors will not be allowed to reschedule their presentation except for religious reasons (as identified in Step 8 of the submission process).

Abstract Withdrawal

Abstracts may be withdrawn by sending an email to abstracts@endocrine.org. Withdrawal requests must be submitted by the submitting (contact) author and include the abstract submission confirmation number. The $150 abstract submission fee is not refundable.

Authorship of Work

Authorship on multiple abstracts is permitted.
LATE BREAKING ABSTRACT SUBMISSION GUIDELINES (Continued)

Awards
The Endocrine Society provides awards to recognize outstanding work in endocrinology. These recognition awards are given to outstanding abstracts submitted by in-training fellows and new faculty whom who have been accepted to present their research during the online annual meeting (ENDO). Honorees will receive a certificate of recognition for their research. Each award has varying criteria. Please visit ENDO Awards to learn more. Winner selection for all awards is based on award criteria and abstract score.

Co-Author and/or Primary Investigator Review
The submitting author (contact) is responsible for ensuring that ALL co-authors and/or primary investigator review the abstract and agree to the Author Agreement and License to Publish prior to submission. Failure to obtain permission to publish from co-authors may result in abstract rejection.

Disposition Notices/Abstract Acceptance
Late Breaking Abstract notifications will be emailed to presenting authors in mid-May. Presenting authors are responsible for communicating the presentation status of their abstract with their co-authors.

Edits
Submitting (contact) authors may log into the site to edit their abstract up until the abstract submission deadline. NO REVISIONS to the abstract or the list of authors will be allowed once the site closes on the deadline date.

Editing Services/Poster Formatting Services
Language editing, translation, and poster formatting services are available through American Journal Experts. Endocrine Society members receive additional 10% off. Visit aje.com/go/esmeetings for more information.

ENDO 2022 Registration
Online registration, PDF registration forms, and program information are available at ENDO 2022 Registration.

Ethical Issues and Conduct
Authors who submit research with or engage in publication ethical violations will be subject to exclusion for future abstract submissions. Review the Ethical Guidelines for Research.

Membership
Membership is not a requirement to submit an abstract for ENDO, but Endocrine Society members receive special discounted ENDO registrations rates. You must be an Endocrine Society member to be considered for abstract awards. Join Now to get the best rate for ENDO.

Payment
A non-refundable fee of $150.00 USD is due at the time of abstract submission. (VISA, MasterCard, and American Express are accepted). If you need to pay with a method other than a credit card, please email abstracts@endocrine.org. Abstract submission does not automatically register you for ENDO. Upon submission, the presenting author of the abstract agrees to register and attend ENDO to present the abstract.
LATE BREAKING ABSTRACT SUBMISSION GUIDELINES (Continued)

Prior Publication Policy

- Submitted abstracts cannot contain data previously presented at a national meeting within the United States at the time of abstract submission.
- Submitted abstracts cannot contain data already accepted for publication in any online or PubMed indexed venue at the time of abstract submission.
- Violators will be subject to abstract withdrawal and may be barred from presenting at future Endocrine Society meetings.

STEPS FOR SUBMITTING YOUR ABSTRACT

Submitting your abstract can take anywhere from 5-30 minutes. You will be prompted to complete the following steps when submitting your abstract. Please review the information below carefully and have available all author names, contact information and disclosure information for entry.

- Step 1: Abstract Title
- Step 2: Presentation Type
- Step 3: Science Type and Topic
- Step 4: Authors and Disclosures
- Step 5: COI and Permissions
- Step 6: Abstract Body
- Step 7: Abstract Keywords
- Step 8: Submission Questions
- Step 9: Awards
- Step 10: Payment
- Step 11: Review Submission

If you are unable to finish your abstract submission in one sitting, you may return to the abstract submission site any time prior to the deadline to complete your submission. All abstracts must be completed and submitted by the abstract submission deadline date at 1:00 PM EST US. If you do not complete this submission prior to the deadline, your abstract will not be reviewed.

Step 1: Abstract title
Abstract titles should be short and specific, and entered in title case. For assistance with putting your abstract title in title case, visit www.capitalizemytitle.com

Step 2: Presentation Type
You may select your abstract to be considered for an Oral Presentation or an e-Poster presentation.

- Oral Presentation: Presenting authors will give a 10-minute presentation using slides to summarize their abstract, followed by 3-5 minutes of audience Q&A. Oral presenters must attend in person in Atlanta, GA.
- Rapid Fire e-Poster Presentation: Presenting authors will give up to a 5-minute presentation highlighting the key points, so interested attendees are wanting to ask questions about your work in the subsequent communications. Select this option if you do not wish to be considered for an oral presentation and want to provide a quick synopsis of your work in person in Atlanta, GA. Presenting authors will upload an e-poster which may be accompanied with a brief 3-5 minute video presentation. e-Posters will be viewable for the duration of ENDO 2022 and presenting authors will receive comments and questions on their poster(s) from meeting participants.
Poster Plus Presentation (Printed Poster + ePoster On Demand): Poster Plus presenters will be assigned one day to display their printed poster at the conference. In addition, poster presenters will be able to stand next to their printed poster during a Meet-and-Greet session in person in Atlanta, GA. Presenting authors will also upload an e-poster and/or 3-5 slides, which may be accompanied with brief 3-5 minute video and audio presentations. e-Posters will be viewable for the duration of ENDO 2022 and presenting authors will receive comments and questions on their poster(s) from meeting participants. The e-Poster Presentations can be viewed on site on 42” plasma screens with a 16:9 aspect ratio. Select this option if you do not wish to be considered for an oral or rapid fire presentation and want to take advantage of presenting your work in-person and via the virtual platform.

e-Poster On Demand: E-posters are an on demand poster option and visible through the entirety of the ENDO 2022 Annual Meeting on the virtual platform and mobile app (if available). There are no physical e-poster presentation times or locations scheduled during the meeting. The e-poster presenting author will have the opportunity to upload their e-poster and a brief 3-5 minute video presentation that can be played on demand. e-Posters will be viewable for the duration of ENDO 2022 and presenting authors will receive comments and questions on their poster(s) from meeting participants.

Step 3: Science Type and Topic
Basic, clinical, and translational scientific abstracts, clinical trials are accepted for submission across 132 topical areas, and clinical case reports are accepted for submission in 16 topical areas. View the complete list of 2022 Abstract Topical Areas.

- **Basic Scientific Research** - Submissions should report basic endocrine research (e.g., physiological or molecular biological research in cell cultures or animal models).
- **Translational Scientific Research** - Submissions should report mechanistic endocrine research in humans, human tissues, tumor cells, or animal models that have a direct relationship to human physiology or disease.
- **Clinical Scientific Research** - Submissions should report endocrine research investigating or concerning specific disease states (e.g., evaluation of diagnostic techniques and therapies).
- **Clinical Trial** - Submissions should report data about the safety or potential benefit of an endocrine intervention such as a medication, device, teaching concept, training method, or behavioral change in human subjects.
- **Clinical Case Report** - Submissions should report valuable/novel teaching points or learning lessons from clinical care of endocrine disorders. In addition to consideration for presentation at ENDO, clinical case reports will be considered for use in other educational formats, online or in print.

For detailed information on submitting abstracts view:
- Submitting a Scientific Abstract
- Submitting a Case Report Abstract
- Submitting a Clinical Trial Abstract

Step 4: Authors and Disclosures
Enter contact information and disclosures for all authors, and the presenting author’s short biography. Edits to authors will not be accepted after the abstract submission site has closed. Please review this information carefully to ensure you have included all abstracts. You may change the presenting author at any time up until the abstract submission site closes.
LATE BREAKING ABSTRACT SUBMISSION GUIDELINES (Continued)

Step 5: Conflict of Interest (COI) and Permissions
Based on the disclosures entered for the presenting author, complete the Conflict of Interest (COI) resolution and recording permissions. If you change presenting authors in Step 4, you must also update this step so the COI and permissions are pertinent to the new presenting author.

Step 6: Abstract Body
Abstracts are text-only (with a 2,500-character limit, including punctuation, but excluding spaces). Graphics (e.g., figures and tables) are not accepted in the body of your abstract. Including references is optional. If references are included, they should be included in your abstract text and will count toward the 2,500-character limit. To preserve the peer review process, do not include any identifying information (e.g., institution or author names) in the body of your abstract (Step 6). All co-authors/primary investigators, their institutional affiliations, and any disclosures must be entered on the Authors page (Step 4).

Step 7: Abstract Keywords
Keywords help others search for and find your abstract when using the ENDO 2022 Program Planner. Select keywords from a drop-down menu that would likely be used to search for your abstract. Minimum of 1 keyword and maximum of 5 keywords.

Step 8: Submission Questions
- Question 1: Abstract Description and Learning Objectives - Provide a brief summary in 200 words that summarizes your abstract in layman terms. For learning objectives, list up to 3 measurable objectives of the knowledge, skills and/or attitude learners will gain upon completion of this educational activity.
- Question 2: Principal Investigator – provide the PI of your research.
- Question 3: Religious Conflicts – indicate if any conflicts exist which would prevent you from presenting on certain days.
- Question 4: Embargo and Publication Restriction – indicate if you do not want your full abstract posted online until the date of your presentation.
- Question 5: Basic Science Pathways - If you are submitting a Basic Science abstract, please select a Science Pathway. Selecting the Basic Science Pathway will help attendees search and find your abstract.
- Question 6: Special Poster Recognition – indicate if you would like your abstract to be considered for special recognition during ENDO 2022. Recognition will be of select top-scoring abstracts from eligible authors.
- Question 7: Cosponsored Meetings – Joint Abstract Submission - The Endocrine Society is cosponsoring abstract submission and review for the ANDROGEN EXCESS & PCOS SOCIETY’S Update Meeting to be held in conjunction with ENDO 2022. Please check the box if you would like your abstract to be considered for presentation at this cosponsored satellite meeting. There is no additional fee.
- Question 8: Quality Improvement and Patient Safety – indicate if the abstract covers quality improvement and patient safety.
- Question 9: Diversity, Equity, and Inclusion – indicate if the topic of the abstract relates to diversity, equity, and inclusion.

Step 9: Awards
The Endocrine Society provides awards to recognize outstanding work in endocrinology. These recognition awards are given to outstanding abstracts submitted by in-training fellows and new faculty whom who have been accepted to present their research during the online annual meeting (ENDO). Please visit endocrine.org/awards for award criteria and more information.
Step 10: Payment
The ENDO 2022 Last Call abstract fee is $150 (USD) per abstract. Abstract fees are non-refundable. Visa, Master Card, and American Express are accepted. If you need to make a wire transfer payment, please email abstracts@endocrine.org for instructions.

AUTHOR AGREEMENT AND LICENSE TO PUBLISH

AUTHORSHIP OF THE WORK
- The Author(s) warrants that the Work in its entirety is original except for those parts that are reproduced or adapted with permission from other sources and acknowledged as such within the Work, that all the facts it contains are true and accurate, and has not been published other than as an abstract in any language or format and has not been accepted elsewhere for print or electronic publication consideration. The Author(s) further warrants that the Work does not contain any material that is defamatory or the publication of which would violate any copyright or other personal, intellectual, property, contract, or proprietary right of any person or entity.

- The Author(s) warrants that each person listed as an author meets the Authorship Conditions and understands the Authorship Obligations described in the Ethical Guidelines for Research on the Endocrine Society's website. All Author(s) consent to the investigation of any improprieties that may be alleged regarding the Work. Each Author(s) further releases and holds harmless the Endocrine Society from any claim or liability that may arise therefrom.

- If the Work has been prepared by an Author(s) as an employee within the scope of his or her employment, the Author(s) represents that the employer has been made aware of, and consents to, the terms of this License. This License includes authorization for the employer to make copies of the Work for its own internal use.

- If all Author(s) are US Government employees and the Work was written as part of the official duties of the Author(s) as employees of the US Government, then the Work may not be subject to US copyright or the ownership provisions of this License. Nevertheless, to the extent allowed by, and consistent with, applicable law, the Author(s) authorize publication of the Work in the Endocrine Society publication under terms equivalent to those provided for in the license and agree to all of the warranties specified in the license.

OWNERSHIP OF THE WORK
- The Endocrine Society acknowledges and agrees that the Author(s) of this Work own all right, title and interest of any nature, throughout the world, to the Work, including any copyright registration or applications for copyright registrations relating thereto anywhere in the world. The Work as defined includes but is not limited to text, figures, tables, artwork, abstracts, cover images, summaries, and supplemental data. Notwithstanding the foregoing, the Endocrine Society may secure copyright registration for any collection or compilation in which the Work is published by the Endocrine Society.

- The Author(s) grants to the Endocrine Society, for the full term of copyright and any extensions thereto a sole and exclusive (except as provided in this Agreement) irrevocable license to publish, sell, reproduce, distribute, transmit, display, store, translate, create derivative works from and otherwise use the Work in any language or in any form, manner, format, or medium now known or hereafter developed without limitation throughout the world, and to permit and/or license others to do any or all of the above.
USE OF THE WORK

- The Author(s) agrees that when reproducing the Work or extracts from it, the Author(s) will credit first publication of the Work in the Endocrine Society publication by name, *Journal of the Endocrine Society*.

*The Author(s) retains the following nonexclusive rights:*

- The Author(s) reserves the right after publication of the Work to use all or part of the Work in compilations or other publications of the Author's own works, and to make copies of all or part of the Work for the Author's use for lectures, classroom instruction, or similar uses.

- The Author(s) reserves the right to post the Work (including the Endocrine Society's formatted PDF) after final publication on the Author(s)'s web page provided that a link to the article in the Endocrine Society's online publication is included, *Journal of the Endocrine Society*.

- The Author(s) reserves the right to post and update the Work on pre-print services provided that the Endocrine Society-formatted files (HTML and PDF) are not used and that a link to the Work in the Endocrine Society's online publication is included, *Journal of the Endocrine Society*.

- The Author(s) reserves the right to deposit his or her final accepted manuscript in the Author(s)'s funding body's archive or designated repository; provided that a link to the Work in the Endocrine Society's online publication is included, *Journal of the Endocrine Society*.

PROTECTION OF THE WORK

- The Author(s) authorizes the Endocrine Society to take such steps as it considers necessary at its own expense in the Author(s)'s name and on their behalf if it believes that a third party is infringing or is likely to infringe the copyright in the Work.

- These Terms are governed by the internal laws of the State of Delaware. The Author(s) agrees that any action arising out of or in any way relating to these Terms may be brought only in a court of competent jurisdiction in the State of Delaware, and the Author(s) hereby consents to the jurisdiction, venue and convenience of such courts. Any waiver of any provision of these Terms will be effective only if it is in writing and signed by the Endocrine Society. No waiver of any provision of these Terms shall be deemed a further or continuing waiver of such provision or any other provision. If any provision of these Terms is found to be invalid, void or unenforceable by any court having competent jurisdiction, the remainder of these Terms shall remain in full force and effect.

Patient Consent (For Case Reports)

- All patients have a right to privacy and personally identifying information should not be revealed without consent. Case reports should follow International Committee of Medical Journal Editors (ICMJE) recommendations. Authors must attest that they have secured all required patient consent forms, to be made available to the Endocrine Society on request. Identifying information, including names, initials, exact dates, or hospital numbers should not be published in written descriptions, figures, or photographs unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the materials to be published. **Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.** The Endocrine Society has the final decision on what information is potentially identifying and when patient consent is required.